Syros Pharmaceuticals, Inc. (SYRS) Revenue History
Annual and quarterly revenue from 2013 to 2023
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SYRS Revenue Growth
SYRS Revenue Analysis (2013–2023)
As of May 8, 2026, Syros Pharmaceuticals, Inc. (SYRS) generated trailing twelve-month (TTM) revenue of $386,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2024) recorded $0 in revenue.
Looking at the longer-term picture, SYRS's 5-year compound annual growth rate (CAGR) stands at +37.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $23.5 million in 2021.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), ARVN (-0.3% YoY), and TNGX (+48.3% YoY), SYRS has underperformed the peer group in terms of revenue growth. Compare SYRS vs KYMR →
SYRS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SYRSCurrent | $386,000 | -100.0% | +37.1% | -1298.2% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 TNGX | $62M | +48.3% | +52.1% | -178.4% |
SYRS Historical Revenue Data (2013–2023)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2023 | $9.9M | -33.2% | $7.7M | 77.3% | $-128,988,000 | -1298.2% |
| 2022 | $14.9M | -36.6% | $11.9M | 80.1% | $-135,873,000 | -913.1% |
| 2021 | $23.5M | +55.6% | $23.5M | 100.0% | $-99,420,000 | -423.3% |
| 2020 | $15.1M | +661.5% | $15.1M | 100.0% | $-82,297,000 | -545.3% |
| 2019 | $2.0M | -3.3% | $2.0M | 100.0% | $-77,741,000 | -3922.4% |
| 2018 | $2.0M | +86.2% | $2.0M | 100.0% | $-64,296,000 | -3136.4% |
| 2017 | $1.1M | +247.3% | $-426,000 | -38.7% | $-54,686,000 | -4966.9% |
| 2016 | $317K | +0.0% | $317K | 100.0% | $-47,963,000 | -15130.3% |
| 2015 | $317K | - | $-285,000 | -89.9% | $-29,820,000 | -9406.9% |
| 2014 | $0 | - | $0 | - | $-13,435,000 | - |
See SYRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSYRS — Frequently Asked Questions
Quick answers to the most common questions about buying SYRS stock.
Is SYRS's revenue growth accelerating or slowing?
SYRS revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +37.1%. TTM revenue fell to $386000.00. This reverses the prior growth trend.
What is SYRS's long-term revenue growth rate?
Syros Pharmaceuticals, Inc.'s 5-year revenue CAGR of +37.1% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is SYRS's revenue distributed by segment?
SYRS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2023 are available for download. Segment mix reveals concentration and diversification trends.